Xuanzhubio-b

Xuanzhubio-b Fundamental Analysis

2575.HKHKSE
HealthcareDrug Manufacturers - Specialty & Generic
HK$12.60
HK$0.81(6.04%)
Hong Kong Market opens in 40h 43m

Xuanzhubio-b Fundamental Analysis

Xuanzhubio-b (2575.HK) shows weak financial fundamentals with a PE ratio of -24.71, profit margin of -4.74%, and ROE of -20.93%. The company generates $0.1B in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

Cash Position11.73%
PEG Ratio-0.25
Current Ratio3.75

Areas of Concern

ROE-20.93%
Operating Margin-4.51%
We analyze 2575.HK's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -434.1/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-434.1/100

We analyze 2575.HK's fundamental strength across five key dimensions:

Efficiency Score

Weak

2575.HK struggles to generate sufficient returns from assets.

ROA > 10%
-14.57%

Valuation Score

Excellent

2575.HK trades at attractive valuation levels.

PE < 25
-24.71
PEG Ratio < 2
-0.25

Growth Score

Weak

2575.HK faces weak or negative growth trends.

Revenue Growth > 5%
N/A
EPS Growth > 10%
N/A

Financial Health Score

Excellent

2575.HK maintains a strong and stable balance sheet.

Debt/Equity < 1
0.00
Current Ratio > 1
3.75

Profitability Score

Weak

2575.HK struggles to sustain strong margins.

ROE > 15%
-2092.95%
Net Margin ≥ 15%
-4.74%
Positive Free Cash Flow
No

Key Financial Metrics

Is 2575.HK Expensive or Cheap?

P/E Ratio

2575.HK trades at -24.71 times earnings. This suggests potential undervaluation.

-24.71

PEG Ratio

When adjusting for growth, 2575.HK's PEG of -0.25 indicates potential undervaluation.

-0.25

Price to Book

The market values Xuanzhubio-b at 4.28 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

4.28

EV/EBITDA

Enterprise value stands at -33.06 times EBITDA. This is generally considered low.

-33.06

How Well Does 2575.HK Make Money?

Net Profit Margin

For every $100 in sales, Xuanzhubio-b keeps $-4.74 as profit after all expenses.

-4.74%

Operating Margin

Core operations generate -4.51 in profit for every $100 in revenue, before interest and taxes.

-4.51%

ROE

Management delivers $-20.93 in profit for every $100 of shareholder equity.

-20.93%

ROA

Xuanzhubio-b generates $-14.57 in profit for every $100 in assets, demonstrating efficient asset deployment.

-14.57%

Following the Money - Real Cash Generation

Operating Cash Flow

Xuanzhubio-b generates limited operating cash flow of $-222.97M, signaling weaker underlying cash strength.

$-222.97M

Free Cash Flow

Xuanzhubio-b generates weak or negative free cash flow of $-223.60M, restricting financial flexibility.

$-223.60M

FCF Per Share

Each share generates $-0.43 in free cash annually.

$-0.43

FCF Yield

2575.HK converts -3.43% of its market value into free cash.

-3.43%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-24.71

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.25

vs 25 benchmark

P/B Ratio

Price to book value ratio

4.28

vs 25 benchmark

P/S Ratio

Price to sales ratio

116.23

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.00

vs 25 benchmark

Current Ratio

Current assets to current liabilities

3.75

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.21

vs 25 benchmark

ROA

Return on assets percentage

-0.15

vs 25 benchmark

ROCE

Return on capital employed

-0.16

vs 25 benchmark

How 2575.HK Stacks Against Its Sector Peers

Metric2575.HK ValueSector AveragePerformance
P/E Ratio-24.7129.60 Better (Cheaper)
ROE-20.93%418.00% Weak
Net Margin-474.21%-11442.00% (disorted) Weak
Debt/Equity0.000.78 Strong (Low Leverage)
Current Ratio3.755.13 Strong Liquidity
ROA-14.57%-74.00% (disorted) Weak

2575.HK outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Xuanzhubio-b's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Fundamental Analysis FAQ